Gastrointestinal Cancers

The use of a chemotherapy-free, combination regimen as a maintenance treatment option was associated with an improvement in survival in a group of patients with advanced pancreatic cancer.

The FDA granted abelacimab a fast track designation for the treatment of thrombosis, a common and sometimes deadly type of blood clot associated with cancer.

From “General Hospital” star Cameron Mathison discussing his cancer experience to Dame Deborah James and Hells Angels founder Sonny Barger dying of the disease, here’s what happened in the cancer space this week.

Recent clinical trial results have given me new hope that one day soon, a cure for all cancers will be found.

Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers.

Recent headlines have been highlighting a monoclonal antibody that eliminated evidence of disease in patients with rectal cancer, but I believe that findings from the research need to be taken with a few grains of caution.

Toby Keith announced in a post on his social media channels that he has been undergoing treatment for stomach cancer since last fall.

The Strata PATH trial will use a novel testing strategy to determine if certain patients with solid tumors can benefit from already-approved therapies.

From Grammy-award winning artist Sheryl Crow discussing her breast cancer journey to a 4-year-old reconnecting with their favorite nurse, here’s what’s happening in the cancer space this week.

The first patient was dosed in the CLAUDIO-01 trial, analyzing SOTO102 in patients with certain types of gastric and pancreatic cancers.

My father was an alcoholic, and though he died in 1992, he lives on through my siblings and me because we all inherited a cancer syndrome from him.

From two celebrity deaths due to cancer to leading American cancer organizations coming together to help patients with cancer fleeing Ukraine, here’s what’s happening in the cancer space this week.

Four sites across the United States are enrolling patients with locally advanced or metastatic pancreatic cancer to see if a novel drug combined with standard-of-care chemotherapy bests chemotherapy alone in survival outcomes and responses to treatment.

Patient sensitivity to chemotherapy prior to surgery could determine if a patient with gastric cancer needs to receive chemo after surgery.

Side effects from cancer treatment with immunotherapy, which may include vitiligo and certain rashes, may point to who will respond better to the treatment, although more research is needed to determine how much weight to put on these data.

Single-agent adagrasib was associated with encouraging treatment responses in patients with previously treated non-colorectal gastrointestinal tumors and pancreatic ductal adenocarcinoma.

Patients with gastric cancer who present with certain bacteria in their gut were found to be more likely to experience skin-related side effects from Opdivo treatment, research showed.

The use of Enhertu was associated with a reduction in the risk of death compared with standard chemotherapy in certain patients with gastroesophageal and gastric cancer.

The FDA will speed up their review of CYNK-101 plus chemotherapy and immune checkpoint inhibitors for the treatment of advanced HER2-postivie gastric or gastroesophageal adenocarcinomas.

From nurse navigators to surgeons, clinical social workers and more, a patient with cancer often has a village of team members helping them achieve a smooth and successful treatment experience.

Communication, self-advocacy and having someone in your corner are all critical tools to bring to a cancer care visit, says an expert from MedStar Georgetown University Hospital.

There are many cancer clinical trials that patients can enroll in across the United States. Here is a snapshot of some of the more recent ones.

The Food and Drug Administration gave clearance to Bold Therapeutics for a phase 1b/2a trial examining treatments for advanced GI cancers.

Aprepitant, palonosetron and dexamethasone curbed chemotherapy-induced nausea and vomiting in certain women with gastrointestinal cancers who were receiving FOLFIRI or FOLFOX regimens.

The indication for the PD-1 blocking antibody now includes adults with mismatch repair-deficient recurrent or advanced disease, adding to the previous indication of endometrial solid tumors.